Paige AI develops AI tools for digital pathology, using deep learning models to analyze pathology slides and assist pathologists in cancer detection and grading. The Paige Prostate tool was the first AI tool to receive FDA approval for cancer detection in pathology, identifying suspicious areas for pathologist review. The company's models have been trained on one of the largest clinical-grade pathology datasets in existence. Pathology labs, cancer centers, and academic medical centers use Paige AI tools to improve the accuracy and efficiency of cancer pathology workflows. The AI serves as a second reader on slides, flagging areas of concern that ensure pathologists don't miss subtle tumor foci. In high-volume labs where pathologists read hundreds of slides per day, AI assistance reduces the attention fatigue that can affect diagnostic accuracy. Paige AI represents the frontier of regulatory-cleared AI in pathology, with multiple FDA-cleared and CE-marked tools in the market. The company's partnership with Microsoft and investment in digital pathology infrastructure positions it for broad deployment as digital slide scanning becomes standard in pathology practice.

What the community says

Paige AI is respected in pathology communities for the regulatory rigor of its cleared tools and the quality of its AI performance. The FDA clearance is cited as essential for institutional adoption and as a marker of clinical validation. Based on community discussions from pathology professional networks and medical AI publications.